Get straight answers on running AI within clinical trials safely. Access practical articles, deep-dive papers and videos on how to optimize your trials without introducing risk.
This webinar gives clinical trial teams a practical roadmap for bringing AI into operations responsibly, using a phased approach that builds the workflow foundation and compliance guardrails each stage of adoption requires.
AI in clinical trials keeps floating untethered — producing answers no one knows what to do with. In this SCOPE X session, AG Mednet CEO Abraham Gutman argues it only becomes deployable when trials run on an orchestrated execution layer that gives every decision and handoff a place to land.
Centralized eligibility review has emerged as a practical strategy that ensures every participant meets inclusion and exclusion criteria, eliminating enrollment-based protocol deviations and enhancing protection of trial integrity and patient welfare.
This webinar highlights common operational failure points and practical approaches that improve endpoint reporting, case processing and adjudicator decision-making while maintaining quality.
Each team in clinical development faces unique workflow challenges. Judi delivers tailored solutions that accelerate protocol execution from start to finish.
The AI-driven process management platform for modern clinical development. Judi unifies fragmented workflows and accelerates execution from protocol to submission.
United States-based medical device sponsor and partner CRO leverage flexibility of Judi for DSMB for novel cardiovascular implant trial with over 100 patients and 25 sites
Multinational biopharmaceutical company engages innovation of Judi in Adjudication for concurrent Phase 3 clinical trials with over 900 patients, and 150 endpoints
Prominent international biotech partners with Judi by AG Mednet and Medrio for holistic solution to remote monitoring and electronic data capture (EDC) on three-year global clinical program of 10 studies
International biopharma sponsor and partner CRO maximize flexibility of Judi in DSMB for Phase 2 multinational clinical program with over 100 patients and 60 sites
European-based biopharma and partner CRO employ dynamic controls of Judi in Adjudication and Site & User Qualification for rare disease immunotherapy trial with over 250 endpoints
Leverage Judi for increased compliance: expedited, high quality, structured decision-making on centralized patient eligibility determination that can eliminate an entire category of important protocol deviations from your trial
